Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Teleflex Incorporated

35 indications, side-by-side phase, drug & LoA

$130.48

+1.17 (+0.9%)

D 31Pipeline Score MedTech · Commercial
Market Cap
5.88 B
EPS
-22.81
P/E Ratio
-
Value Trade
84.26 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    548.26 M

  • R&D Expenses

    44.39 M

  • Operating CF

    46.66 M

  • Total Assets

    6.78 B

  • Total Liabilities

    3.70 B

  • Equity

    3.08 B

  • D/E Ratio

    12,345

2.08 %
Week
-2.39 %
1 Month
19.35 %
3 Month
26.15 %
6 Month
-66.9 %
5 Year
30,579.24 %
All Time
Cash Data
Profitable

  • Cash Position

    329.55 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 7, 2026
Overview
Volume
391.27 K
52 Week Range
100.18 - 139.67
% held by Insiders
0.7 %
% held by Institutions
109.87 %
Enterprise Value
8.24 B
Total Shares
44.24 M
Short %
5.5 %
Float Shares
43.40 M
Company Description
HQ: 550 E SWEDESFORD RD, WAYNE, PA...
Employees:15,500
https://www.teleflex.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D31
Pipeline Score
$189M
Pipeline Value
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 29%
Small Cap
(rank 644 of 905)
Percentile Rank
Teleflex Incorporated faces pipeline headwinds (31/100), with $290M risk-adjusted pipeline value, led by Arterial Sealing in Hemostasis of Arterial Punctures (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Arterial Sealing
Unknown		Hemostasis of Arterial PuncturesPhase 3NCT0038828457% $286M COMPLETED 270 - -Mar 1, 2007 -Dec 9, 2015
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in TFX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
TFX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TFX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
TFX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
TFX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
TFX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
2026-06-180 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Teleflex Incorporated (TFX) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How TFX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
All entries for TFX are observational/device studies. Toggle "Show observational" to view them.